ArticleCurrent microbiology2026
Phage Intolerance Impacts Antibiotic Susceptibility and Virulence in Staphylococcus aureus.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage therapy is a promising alternative to the growing problem of antibiotic-resistance. However, bacterial phage-resistance may develop, compromising therapy. Phage-resistance has primarily been associated with changes in phage receptors that in the human pathogen, Staphylococcus aureus, are the cell-wall linked wall teichoic acids (WTA) which can be modified by glycosylation. With the aim of identifying factors contributing to phage-resistance, we exposed S. aureus to lytic K-type myo-viruses, namely phage K, ϕIPLA-RODI and Stab21 to obtain resistant clones. Out of 9 phage-resistant mutants, a third harbored mutations in cell-wall genes previously linked to phage resistance, namely in femA, involved in peptidoglycan crossbridge formation, and tagO, encoding the initiator of the WTA biosynthesis. The remaining mutants had mutations in pathways not previously associated with phage-resistance, with three in deoC1 involved in nucleoside catabolism, two in potA and potB, respectively, involved in polyamine import and one in the RNA helicase, cshA. When assessing virulence in Galleria mellonella and antibiotic susceptibility as well as WTA glycosylation, our results showed diverse effects. As expected, mutations in the wall teichoic acid synthesis pathway increased β-lactam sensitivity and attenuated virulence in a G. mellonella model. In contrast, the cshA mutation increased both virulence and susceptibility to β-lactams. Increased virulence was also seen for a mutant with several mutations including femA. Further phage susceptibility appeared not to be strictly correlated with WTA glycosylation patterns. Our findings show that in S. aureus reduced phage susceptibility can be caused by mutations affecting central metabolic processes and can have unpredictable consequences for antibiotic susceptibility and virulence. Our results emphasize the need for evaluating evolutionary trade-offs before clinical phage therapy deployment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.